Stock Scorecard
Stock Summary for Agios Pharmaceuticals Inc (AGIO) - $40.00 as of 11/5/2025 1:21:46 PM EST
Total Score
9 out of 30
Safety Score
45 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for AGIO
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for AGIO
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for AGIO
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for AGIO
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for AGIO (45 out of 100)
| Stock Price Rating (Max of 10) | 8 |
| Historical Stock Price Rating (Max of 10) | 8 |
| Stock Price Trend (Max of 10) | 9 |
| Book Value (Max of 10) | 7 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 3 |
| Analyst Strong Buy Ratings (Max of 5) | 4 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 6 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for AGIO
Financial Details for AGIO
Company Overview |
|
|---|---|
| Ticker | AGIO |
| Company Name | Agios Pharmaceuticals Inc |
| Country | USA |
| Description | Agios Pharmaceuticals, Inc. is a prominent biopharmaceutical company headquartered in Cambridge, Massachusetts, dedicated to developing transformative therapies targeting diseases related to cellular metabolism. With a strong focus on oncology and rare genetic disorders, Agios utilizes its extensive knowledge of metabolic pathways to create innovative treatments that exemplify precision medicine. The company boasts a promising pipeline and actively engages in strategic collaborations to enhance research and development efforts, demonstrating its commitment to advancing scientific understanding and significantly improving patient outcomes through state-of-the-art therapeutic solutions. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 9/30/2025 |
| Next Earnings Date | N/A |
Stock Price History |
|
| Last Day Price | 40.00 |
| Price 4 Years Ago | 32.87 |
| Last Day Price Updated | 11/5/2025 1:21:46 PM EST |
| Last Day Volume | 711,169 |
| Average Daily Volume | 563,669 |
| 52-Week High | 62.58 |
| 52-Week Low | 23.41 |
| Last Price to 52 Week Low | 70.87% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 43.17 |
| Sector PE | 78.24 |
| 5-Year Average PE | -4.29 |
| Free Cash Flow Ratio | 25.16 |
| Industry Free Cash Flow Ratio | 14.51 |
| Sector Free Cash Flow Ratio | 28.54 |
| Current Ratio Most Recent Quarter | 13.82 |
| Total Cash Per Share | 1.59 |
| Book Value Per Share Most Recent Quarter | 22.04 |
| Price to Book Ratio | 1.69 |
| Industry Price to Book Ratio | 33.29 |
| Sector Price to Book Ratio | 33.29 |
| Price to Sales Ratio Twelve Trailing Months | 52.25 |
| Industry Price to Sales Ratio Twelve Trailing Months | 30.27 |
| Sector Price to Sales Ratio Twelve Trailing Months | 15.92 |
| Analyst Buy Ratings | 3 |
| Analyst Strong Buy Ratings | 2 |
Share Statistics |
|
| Total Shares Outstanding | 58,314,000 |
| Market Capitalization | 2,332,560,000 |
| Institutional Ownership | 110.79% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | 291.35% |
| Reported EPS 12 Trailing Months | -7.01 |
| Reported EPS Past Year | -5.26 |
| Reported EPS Prior Year | -6.35 |
| Net Income Twelve Trailing Months | -401,265,000 |
| Net Income Past Year | 673,725,000 |
| Net Income Prior Year | -352,088,000 |
| Quarterly Revenue Growth YOY | 43.70% |
| 5-Year Revenue Growth | -20.91% |
| Operating Margin Twelve Trailing Months | -907.00% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 92,710,000 |
| Total Cash Past Year | 76,247,000 |
| Total Cash Prior Year | 88,205,000 |
| Net Cash Position Most Recent Quarter | 92,710,000 |
| Net Cash Position Past Year | 76,247,000 |
| Long Term Debt Past Year | 0 |
| Long Term Debt Prior Year | 0 |
| Total Debt Most Recent Quarter | 0 |
| Equity to Debt Ratio Past Year | 1.00 |
| Equity to Debt Ratio Most Recent Quarter | 1.00 |
| Total Stockholder Equity Past Year | 1,540,956,000 |
| Total Stockholder Equity Prior Year | 811,019,000 |
| Total Stockholder Equity Most Recent Quarter | 1,284,330,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -414,094,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -7.10 |
| Free Cash Flow Past Year | -391,526,000 |
| Free Cash Flow Prior Year | -297,061,000 |
Options |
|
| Put/Call Ratio | 3.95 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.98 |
| MACD Signal | 1.08 |
| 20-Day Bollinger Lower Band | 33.33 |
| 20-Day Bollinger Middle Band | 38.62 |
| 20-Day Bollinger Upper Band | 43.91 |
| Beta | 0.83 |
| RSI | 59.29 |
| 50-Day SMA | 36.01 |
| 150-Day SMA | 32.72 |
| 200-Day SMA | 31.26 |
System |
|
| Modified | 11/4/2025 4:45:33 PM EST |